




Georgios Skretas, PhD

Director

Institute for Bio-innovation Biomedical Sciences Research Center "Alexander Fleming"

E-mail skretas@fleming.gr

Telephone +302109656310 . 182

Research Biomolecular engineering, synthetic biology, protein misfolding and aggregation, biocatalysis

Keywords Biomolecular engineering, synthetic biology, protein misfolding and aggregation, protein and peptide engineering, Alzheimer's disease, amyotrophic lateral sclerosis,

Links PubMed: <https://pubmed.ncbi.nlm.nih.gov/?term=skretas+g&sort=date>
Scholar: <https://scholar.google.gr/citations?user=61wV5vIAAAAJ&hl=en>
LinkedIn: https://www.linkedin.com/in/georgios-skretas-4aa1334/?trk=public_post-text&originalSubdomain=gr
Webpage: <https://www.fleming.gr/research/ibi>

Biography

Georgios Skretas received his Bachelor's degree from the School of Chemical Engineering, National Technical University of Athens (Greece) in 1998 and his PhD in Chemical and Biological Engineering from Princeton University (USA) in 2006. He then worked as a post- doctoral research associate at the Institute of Cell and Molecular Biology of the University of Texas at Austin (USA) (2006-2009). In 2010, he received a Marie Curie International Reintegration Fellowship to return to Greece and establish his independent research group in his home country. During 2010-2022, he served as Head of the Laboratory of Enzyme and Synthetic Biotechnology and the Institute of Chemical Biology of the National Hellenic Research Foundation (Greece). Since 2022, he is the Director of the Institute for Bio-innovation at the Biomedical Sciences Research Center "Alexander Fleming"(BSRC Fleming). Georgios Skretas has been awarded a Consolidator Grant by the European Research Council (ERC) (2019-2024), and ERC Proof-of-Concept Grant and a grant by the European Commission to establish an ERA Chair in Biomolecular Engineering and Synthetic Biology at BSRC Fleming (2023-2027). He is inventor in four (4) patents/patent applications. He is the Founder and Chief Executive Officer of ResQ Biotech, a spin-off company applying synthetic biology approaches to advance early-stage drug discovery against diseases caused by protein misfolding, such as Alzheimer's disease. INCLUDEPICTURE "http://scholar.uoa.gr/sites/default/files/smyrnis/files/img_8302.jpg" * MERGEFORMATINET